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Abstract: In the light of new cases of progressive multifocal leukoencephalopathy and induced 
autoimmunity in multiple sclerosis (MS) patients who received treatment with upcoming 
disease-modifying immunosuppressant drugs with a highly specific mode of action such as 
natalizumab, rituximab, or alemtuzumab, alternative oral treatment options for a subgroup of less 
severely affected MS patients are a major focus of drug development. These agents are currently 
investigated in phase III clinical trials and some of them are characterized by a favorable safety 
profile. With an emphasis on teriflunomide, the active metabolite of an immunosuppressant 
approved for the treatment of rheumatoid arthritis since 1998, a number of oral treatment options 
for patients with MS are discussed.
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Introduction
Since 1990, therapy for multiple sclerosis (MS) has dramatically improved. 
Immunomodulatory therapies of the first generation, including interferon-β (IFN-β) 
and glatiramer acetate, have become the standard of care in relapsing–remitting 
MS.1 The main advantage of those agents is their established positive safety profile, 
although efficacy is only partial. Unfortunately, the subcutaneous or intramuscular 
mode of application and local adverse effects at the sites of injection impair quality 
of life of and long-term acceptance by patients. Thus, new drugs for MS therapy 
have to prove to be superior to standard therapy in respect to efficacy, but also need 
to display a reasonable safety profile. In addition, intravenous and oral formulations 
might help to increase the rate of early treatment and overall compliance. Natalizumab, 
a monoclonal antibody directed against the alpha4-beta1-integrine, was the first drug 
of a second generation of immunoactive agents, approved by the US Food and Drug 
Administration (FDA) and European Medicines Agency (EMEA) for highly active 
MS or MS refractory to first line treatment. It has been specifically designed to target 
a critical step of leukocyte extravasation from the blood into the central nervous 
system.2,3 Phase III clinical trials have clearly shown its advantages: high efficacy 
and a maximum of compliance by intravenous monthly infusion.4,5 Immediately 
after completion of a phase III trial that led to its approval by the FDA, safety issues, 
and most notably the risk of progressive multifocal leukoencephalopathy (PML), 
became apparent.6–8 Restriction of natalizumab to patients with highly active MS or 
patients, not responding to first line treatment, was not congruent with the inclusion 
criteria of these studies but based on risk–benefit considerations. Just recently, new Neuropsychiatric Disease and Treatment 2009:5 334
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cases of PML occurring in patients receiving natalizumab 
monotherapy have been published and the long-term safety 
data will decide how broadly this drug can be administered 
to patients.9,10 Interestingly, this safety issue is most likely not 
restricted to natalizumab, but is also relevant for other cur-
rently investigated monoclonal antibodies, including ritux-
imab or alemtuzumab.11,12 Although the mode of action of 
these drugs is highly specific, their administration to patients 
apparently goes along with an increased risk of potential 
life threatening infectious (eg, risk of progressive multifo-
cal leukoencephalopathy in natalizumab or rituximab) or 
autoimmune (eg, risk of autoimmune thrombocytopenia and 
thyroid disease in alemtuzumab)13 complications. As MS is a 
disease of low mortality in a young population and treatment 
primarily seems to be effective in the early inflammatory 
state of disease when patients suffer only from a low grade 
of impairment/disability, the risk–benefit consideration is 
crucial. Although low, the risk of a potential life-threatening 
complication in the MS population demands critical patient 
selection for the second generation of immunosuppressants 
and high standards of safety surveillance plans. Thus, in 
parallel with the development of new monoclonals targeting 
specific critical steps not only of autoimmunity but also of 
immunosurveillance and resistance to infections, concepts 
of more general modes of action resulting in a less severe 
immunosuppression have been tested in clinical trials. In the 
context of these studies, oral formulations are highly appre-
ciated by patients, improving quality of life, and increas-
ing adherence to therapy.14–16 Oral immunomodulatory or 
immunosuppressant drugs characterized by a maximum of 
compliance combined with a good safety–benefit ratio will 
likely become the third category of drugs available for MS 
treatment in the nearer future.
Teriflunomide and its mode  
of action
One promising oral agent in the treatment of MS is 
teriflunomide, the active metabolite of leflunomide, an 
approved therapy for rheumatoid arthritis since 1998.17–20 
The ability to noncompetitively and reversibly inhibit the 
mitochondrial enzyme dihydro-orotate dehydrogenase 
(DHODH), relevant for the de novo synthesis of pyrimidine, 
is believed to exert the most important therapeutic effect.21–24 
By inhibiting DHODH and diminishing DNA synthesis, 
teriflunomide has a cytostatic effect on proliferating B and 
T cells.25 In addition, teriflunomide inhibits protein tyrosine-
kinase activity, reducing T-cell proliferation, activation, and 
production of cytokines.26–28 A more recent study showed that 
teriflunomide also interferes with the interaction between 
T cells and antigen-presenting cells (APC) crucial for T cell 
immune responses.29 Furthermore, there is some evidence that 
teriflunomide might block tumor necrosis factor-α (TNF-α) 
induced nuclear factor κB (NF κB) activation,30 inhibit cell 
adhesion molecules and matrix metalloproteinases.31,32 Also, 
in vitro data proved teriflunomide to diminish oxygen free-
radical production and neutrophil chemotaxis, to augment 
levels of the immunosuppressive cytokine transforming 
growth factor-β1 (TGF-β1) and to inhibit cyclooxygenase-2 
activity.32–35
Pharmacokinetics
Phase II clinical trials for leflunomide showed that 
teriflunomide is highly protein bound in plasma (99.3%) 
and has a low distribution volume. Its half-life is about 
two weeks in humans. It is cleared by hepatic metabolism 
and enterohepatic circulation can be prevented by 
cholestyramine decreasing the half-life of the drug to 
one or two days.36 Teriflunomide inhibits the cytochrome 
p450 2C9 isoenzyme and thereby enhances the anticoagu-
lant effect of warfarin.36 Because its excretion is mainly 
hepatic, leflunomide is not contraindicated in renal insuf-
ficiency, although it should be used with caution in these 
circumstances.37
Effects of leflunomide  
and teriflunomide on experimental 
autoimmune encephalomyelitis
Studies in experimental autoimmune encephalomyelitis 
(EAE)–an animal model of MS–showed the immunomodu-
latory potential of leflunomide as well as of teriflunomide 
and proved both agents to be effective in ameliorating the 
disease course. In one study, the effect on disease activity was 
investigated in a T helper cell type 1 cell-borne monophasic 
disease model induced in Lewis rats by adoptive transfer of 
myelin basic protein (MBP)-specific T cell lines. In 12 Lewis 
rats treated with leflunomide for seven days, leflunomide 
suppressed clinical signs of EAE. Interestingly, significantly 
reduced motor disability was observed even in uridine-
substituted animals suggesting additional mechanisms of 
action independent from the depletion of cellular pyrimidine. 
In vitro, MBP-specific T cell lines that had been antigen-
activated in the presence of teriflunomide produced less IFN-γ 
and showed reduced chemotaxis.38 Just recently, a study in a 
Dark Agouti rat model of EAE showed teriflunomide to be 
effective in reducing behavioral, electrophysiological, and 
histopathological deficits.39 The Dark Agouti rat model of Neuropsychiatric Disease and Treatment 2009:5 335
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EAE is believed to more closely mimic the chronic clinical 
course in MS40 and is induced by a single subcutaneous 
injection of rat spinal cord homogenate. Teriflunomide 
delayed disease onset and decreased disease severity in 
this model in a dose-dependent manner. In addition, histo-
pathological data demonstrated inhibition of up to 90% of 
inflammation, demyelination, and axonal loss. Furthermore, 
therapeutic dosing of teriflunomide prevented delayed 
conduction and a decrease in the amplitude of somatosensory 
evoked potentials.39
Results of phase II clinical trial
Study design
In 2006, the first randomized, double-blind, placebo-controlled 
phase II study to assess efficacy and safety of oral teriflunomide 
in MS-patients with relapses was published.41 One hundred and 
seventy nine patients with relapsing–remitting MS (n = 157) 
or secondary progressive MS with relapses (n = 22) and an 
Expanded Disability Status Scale (EDSS)42 score of 6 were 
randomized to receive either placebo (n = 61), teriflunomide 
7 mg/day (n = 61) or teriflunomide 14 mg/day (n = 57). 
Patients aged 18 to 65 years with clinically confirmed MS43,44 
were eligible for the trial. Patients were required to have two 
documented relapses within the previous three years and one 
during the preceding year. Patients on other immunosuppres-
sant or immunomodulatory drugs within four months prior to 
the trial, except for corticosteroids, were excluded. Both male 
and female patients had to practice effective contraception 
during the trial and for 24 months after drug discontinua-
tion or undergo a washout procedure. Magnetic resonance 
imaging (MRI) scans were performed every six weeks during 
the treatment phase of 36 weeks and activity was measured 
by pre- and postgadolinium-enhanced T1-weighted (T1 and 
T1-Gd) and by T2-weighted (T2) sequences. The primary 
efficacy endpoint was the number of combined unique (CU) 
active lesions (a combination score of the number of new and 
persisting Gd-T1 and T2 lesions) per MRI scan during the 36-
week treatment phase. Secondary outcomes were MRI-based 
and included the number of T1- lesions, the number of T2 
lesions, the number of patients with CU active, T1 and T2 active 
lesions and the percentage change from baseline to endpoint 
in burden of disease (measured in T2 lesion volume). Second-
ary clinical measures included the number of patients with 
MS relapses, the annualized relapse rate, and the number of 
relapsing patients requiring a course of steroids. In addition, the 
number of patients with an increase in disability was assessed, 
measured in an increase in EDSS 1 in patients with a baseline 
EDSS score of  5.5 or an increase in EDSS score of  0.5 in 
patients with a baseline EDSS score  5.5. EDSS rating was 
performed every 12 weeks during treatment phase.
Efficacy of teriflunomide on MRI 
surrogate markers
Treatment with either teriflunomide 7 or 14 mg/day resulted 
in the significant suppression of 61.1% or 61.3%, respectively 
(p  0.03 or p  0.01) of MRI activity measured in the mean 
number of CU active lesions per scan (Figure 1).
The decrease of cumulative mean number of CU lesions 
became significant by 12 weeks and was maintained for the 
full 36 weeks of treatment period. Regarding secondary 
MRI-endpoints, teriflunomide 7 or 14 mg/day also signifi-
cantly reduced the median number of T1 and T2 lesions per 
scan over the treatment period. In addition, the number of 
patients with T1, CU active and T2 lesions was lower in both 
of the teriflunomide-treated groups. Finally, the burden of 
disease measured in the median change from baseline was 
significantly diminished in the teriflunomide 14 mg/day 
group (-4.1% versus 5.2%, p  0.02).
Efficacy of teriflunomide on clinical 
measures
The proportion of patients showing an increase in disability 
measured on the EDSS score at endpoint versus baseline was 
significantly lower in the 14 mg/day teriflunomide group com-
pared with placebo (7.4% versus 21.3%; p  0.04). Annualized 
relapse rates were lower in both treatment groups compared to 
placebo without reaching statistical significance. Although not 
significant, a greater proportion of patients (77% versus 62%) 
was relapse-free in the 14 mg teriflunomide group and less 
patients in this group required steroids compared to placebo 
(14% versus 23%).
The safety profile of leflunomide
Leflunomide was first approved for treatment of rheumatoid 
arthritis in 1998. Based on the experience in this indication, its 
active metabolite teriflunomide seems to have a comparably 
well investigated safety profile. The most common adverse 
effects associated with leflunomide are gastrointestinal 
symptoms (diarrhea, dyspepsia, nausea/vomiting, abdominal 
pain, oral ulcers).18,19,45–48 Most of these symptoms decline after 
the first two weeks of treatment. Liver toxicity, most prominent 
in patients with pre-existent liver disease or concurrent use of 
other hepatotoxic drugs, seems to be one of the most serious 
safety issues. In the 2003 Cochrane review, the pooled absolute 
risk difference is calculated with 8% and the number needed to 
treat in order to have one person with elevated liver function Neuropsychiatric Disease and Treatment 2009:5 336
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tests was 12.5.19 In rare cases, severe hepatic injury with fatal 
outcome in some patients occurred in the post-marketing 
phase of leflunomide in rheumatoid arthritis.49 Because of 
an increased risk within the first six months of treatment, a 
monthly check of liver enzymes has been recommended and 
if stable, every six to eight weeks thereafter.36 Mild allergic 
reactions in the leflunomide group were more likely to occur 
when compared to placebo.19 Further adverse effects are 
reversible alopecia, rash, mild weight loss and headache.46,50 
There is a low risk of leukopenia and pancytopenia.50–52 
Although infection rates were not found to be significantly 
different between leflunomide and placebo in patients with 
rheumatoid arthritis within randomized trials,19,53 there is 
some evidence from the post marketing period for a slightly 
elevated risk of opportunistic exogenous and endogenous 
infections. Cases of pulmonary tuberculosis, Pneumocystis 
jieroveci pneumonia and other pulmonary infections have been 
reported.54 One case of PML in a patient with systemic lupus 
erythematosus on leflunomide was observed.55 However, this 
patient had been treated with various other immunosuppressant 
drugs before (prednisone, azathioprin, chloroquine, danazol, 
cyclosporine A, methotrexate), and was switched from 
methotrexate to leflunomide about five months before onset of 
PML symptoms. The incidence of drug-related hypertension 
ranges between 1.1% and 6.8%.46,47,50,56 Leflunomide was 
found to be teratogenic when administered to rats, rabbits, 
and mice.36,57–59 Therefore, leflunomide and its metabolite 
are considered to be teratogenic in human and are contrain-
dicated in pregnancy. Based on animal data, teriflunomide 
levels 0.02 mg/L on two occasions 14 days apart before 
pregnancy are considered to have minimal risk. As mentioned 
above, drug clearance is accelerated by administration of chole-
styramine.36 No malignancies in patients receiving leflunomide 
for rheumatoid arthritis have been observed so far.
The safety profile of teriflunomide
For the use of teriflunomide in MS in the 2006 published 
phase II clinical trial, serious adverse events (SAE) have 
been reported in 19 patients including elevated liver 
enzymes, hepatic dysfunction, neutropenia, rhabdomy-
olysis, and trigeminal neuralgia without any significant 
differences between the groups (teriflunomide 7 mg/day: 
five SAE, teriflunomide 14 mg/day: seven SAE, placebo: 
seven SAE). Nasopharyngitis, alopecia, nausea, increases 
in alanine aminotransferase levels, paresthesia, back pain, 
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Figure 1 Efficacy of teriflunomide on the primary outcome measure in the phase II study. Neuropsychiatric Disease and Treatment 2009:5 337
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reported in patients on teriflunomide without any significant 
differences between the groups. Adverse events (AE) 
resulting in study exit were observed in 15 patients (four in 
placebo, three in teriflunomide 7 mg/day and eight in teriflu-
nomide 14 mg/day). Six patients were withdrawn form the 
study because of abnormal alanine aminotransferase levels 
(three in placebo, one in teriflunomide 7 mg/day, and two 
in teriflunomide 14 mg/day), other reasons for withdrawal 
were alopecia, erythema multiforme, urticaria, condyloma 
accuminatum, dyspepsia, and hypertension. There were no 
deaths in any of the treatment groups.41
Ongoing studies of teriflunomide  
in MS
Currently two phase III studies investigate the effect of 
teriflunomide 7 and 14 mg/day versus placebo on clinical 
endpoints, the annualized relapse rate, and the accumulation 
of disability measured in EDSS. Final data collection dates 
for above mentioned trials on primary outcome measures 
are expected in October 2010 and in September 2011.60 
There is currently one phase III trial studying the ability of 
teriflunomide to delay conversion of the clinically isolated 
syndrome to definite MS (time frame of two years), its primary 
completion date is expected to be in April 2011. Two phase II 
clinical studies investigate safety of teriflunomide when added 
to either glatiramer acetate or interferon β. In addition, safety-
extension trials are ongoing for the 2006 published phase II 
study and are also planned for phase III clinical trials.60
Perspective:   Teriflunomide’s 
potential role in the treatment  
of MS
Teriflunomide is currently one of five oral agents tested in 
phase III clinical studies for the treatment of relapsing–remitting 
forms of MS (Table 1).
While previous clinical trials consistently showed supe-
rior efficacy of each single compound compared with placebo 
regarding different MRI based primary outcome measures, 
most agents still have to show to be more effective on clinical 
endpoints in the currently recruiting trials. As documented 
for high-dose teriflunomide, some of the oral drugs already 
have proven to impact beneficially on relapse rate or sus-
tained disability. In phase III trials, comparative outcomes 
between the tested agent and the first line therapy (glatiramer 
acetate or IFN-β) will decide about the future drug ranking 
and modalities of approval. Although different forms of 
application make a double blind approach more challenging, 
the rater blinded study directly comparing alemtuzumab to 
IFN-β1a published recently showed the advantage of this 
study concept.13 However, at the same time this trial showed 
alemtuzumab to be superior to standard therapy regarding 
efficacy, it also brought up safety issues, predominantly 
the issue of induced secondary autoimmunity.13 Additional 
cases of PML in MS under monotherapy of natalizumab 
have already increased the efforts to control risks, to identify 
certain patients at risk but also to look for other therapeutic 
options especially for less severely affected patients.9 In this 
respect, given the long-term favorable experience gathered 
with leflunomide in the treatment of rheumatoid arthritis, teri-
flunomide appears more promising than other drugs currently 
evaluated. New oral agents, eg, the sphingosin-1 phosphate 
receptor superagonist FTY720/fingolimod, clearly, like 
other powerful immunointerventional strategies, require 
close monitoring in a possible post-marketing setting when 
administered to a comparably young population with almost 
normal life expectancy. The risks and disadvantages of leflu-
nomide have been studied for years in a population similar 
to MS patients. While hepatotoxicity seems to be manage-
able with close laboratory monitoring, washout procedures 
already have been defined in the face of the slightly increased 
risk of infection and to accelerate drug clearance in women 
who wish to become pregnant. Therefore, administration of 
teriflunomide to MS patients seems to be comparable safe.
Looking at currently running phase II clinical trials, the 
idea of combination therapy as an add-on to the established 
first line therapy is of growing interest. A key question in 
those trials is whether or not the two combined agents have an 
additive effect in a complex not yet fully understood autoim-
mune disease.65 The ideal combination would yield additive 
or even super-additive, synergistic effects regarding efficacy, 
without increasing toxicity. Phase II clinical trials for combi-
nation therapy including teriflunomide and other oral drugs 
might bring up further therapeutic options. Regarding the 
safety profile of leflunomide, there is some evidence of an 
increased frequency of hepatotoxicity or infectious complica-
tions when combined with other immunosuppressants, eg, 
methotrexate.66 Notably, one case of PML in a patient with 
systemic lupus erythematodes on leflunomide after treatment 
with various other immunosuppressants emphazises the need 
for critical assessment and vigorous monitoring.55
Looking at study completion dates, oral immunomodula-
tory or immunosuppressant drugs are most likely to enlarge the 
arsenal of approved drugs for MS within the next years. The 
results of these trials need to be carefully reviewed to develop 
a consensus about which drug should be administered to an Neuropsychiatric Disease and Treatment 2009:5 338
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individual patient. If promising results of phase II trials can be 
replicated in phase III, given its well investigated safety profile, 
teriflunomide could be one of the first oral drugs available.
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